### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. <u>n/a</u>)\*

# UroGen Pharma Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.01 per share

(Title of Class of Securities)

#### M96088105

(CUSIP Number)

#### December 31, 2020

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

x Rule 13d-1(b)

o Rule 13d-1(c)

o Rule 13d-1(d)

E

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

M960	88105					
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) CREDIT SUISSE AG/ 000000000						
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)						
(a) o						
CITIZENSHIP OR PLACE OF ORGANIZATION						
Switzerland						
		SOLE VOTING POWER				
	5	0				
		SHARED VOTING POWER				
	6	1,121,071				
NUMBER OF SHARES		SOLE DISPOSITIVE POWER				
CIALLY	7	0				
СН		SHARED DISPOSITIVE POWER				
	8	1,121,071				
AGGRE	GATE	AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
1,121,071						
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)						
0						
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
5,07%						
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)						
BK, HC						
	NAMES I.R.S. II CREDIT 0000000 CHECK (a) o (b) x SEC US CITIZEI Switzerl Switzerl Switzerl Switzerl Switzerl CITIZEI Switzerl Switzerl Switzerl CITIZEI Switzerl Switzerl Switzerl CITIZEI Switzerl Switzerl CITIZEI Switzerl Switzerl Switzerl CITIZEI Switzerl Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI Switzerl CITIZEI SWITZEI SWITZEI SWITZEI SWITZEI CITIZEI SWITZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI SWITZEI CITIZEI SWITZEI SWITZEI CITIZEI SWITZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITIZEI SWITZEI CITI	I.R.S. IDENTIF CREDIT SUISS 00000000 CHECK THE A (a) o (b) x SEC USE ONL SEC USE ONL SWITTE SWITTE SWITTE AGGREGATE 1,121,07 CHECK IF THI o PERCENT OF 5,07% TYPE OF REPO				

FOOTNOTES

### Item 1.

	(a)	Name of Issuer UroGen Pharma Ltd.
	(b)	Address of Issuer's Principal Executive Offices 9 HA'TA'ASIYA ST RA'ANANA L3 4365007 972 9 770 7601
Item 2.		
	(a)	Name of Person Filing CREDIT SUISSE AG/
	(b)	Address of Principal Business Office or, if none, Residence Uetlibergstrasse 231 P.O. Box 900 CH 8070 Zurich, Switzerland
	(c)	Citizenship Switzerland

- (d) Title of Class of Securities Ordinary Shares, par value NIS 0.01 per share
- (e) CUSIP Number M96088105

## Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)	0	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).
(b)	Х	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
(c)	0	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
(d)	0	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
(e)	0	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
(f)	0	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
(g)	х	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	0	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	0	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	0	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
(k)	0	A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii) (J), please specify the type of institution:

### Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 1,121,071
- (b) Percent of class: 5,07%
- (c) Number of shares as to which the person has:
  - (i) Sole power to vote or to direct the vote: 0
  - (ii) Shared power to vote or to direct the vote: 1,121,071
  - (iii) Sole power to dispose or to direct the disposition of: 0
  - (iv) Shared power to dispose or to direct the disposition of: 1,121,071

### Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o .

N/A

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

See EX 99.1

### Item 8. Identification and Classification of Members of the Group

N/A

Item 9. Notice of Dissolution of Group

N/A

Item Certification 10.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

### **Credit Suisse AG**

Date: February 12, 2021

By: /s/ Robert Andric Name: Robert Andric Title: Director

Footnotes:

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

In accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998), this Statement is being filed by Credit Suisse AG (the "Bank"), a Swiss bank, on behalf of its subsidiaries to the extent that they conduct business as the Swiss Universal Bank, Asia Pacific, International Wealth Management, Global Markets, Investment Banking & Capital Markets and the Strategic Resolution Unit operating divisions (collectively, the "Divisions" and together with the Bank and its subsidiaries, the "Reporting Person"). The address of the principal business and office of the Bank is Uetlibergstrasse 231, P.O. Box 900, CH 8070 Zurich, Switzerland. The address of the principal business and office of the Reporting Person in the United States is Eleven Madison Avenue, New York, New York 10010. The ultimate parent company of the Bank is Credit Suisse Group AG ("CSG"), a corporation formed under the laws of Switzerland. CSG is a global financial services company, active in all major financial centers and providing a comprehensive range of banking products.

The Bank is comprised of three regionally focused divisions: Swiss Universal Bank, Asia Pacific and International Wealth Management serving Europe, the Middle East, Latin America and Africa. Two other divisions—Global Markets as well as Investment Banking & Capital Markets—sit alongside these regional businesses. The Strategic Resolution Unit consolidates, as of December 31, 2018, the Bank's remaining portfolios from the former non-strategic units plus additional businesses and positions that do not fit with its strategic direction. The business address of CSG is Paradeplatz 8, P.O. Box 1, CH 8070 Zurich, Switzerland. CSG, for purposes of the federal securities laws, may be deemed ultimately to control the Bank and the Reporting Person. CSG, its executive officers and directors, and its direct and indirect subsidiaries may beneficially own securities to which this Statement relates (the "Shares") and such Shares are not reported in this Statement. CSG disclaims beneficial ownership of Shares beneficially owned by its direct and indirect subsidiaries, including the Reporting Person. Each of the Divisions disclaims beneficial ownership of Shares beneficially owned by the Reporting Person. The Reporting Person disclaims beneficially owned by CSG and each of the Divisions.